Are all statins created equal? [1]
dc.contributor.author | Maritz F.J. | |
dc.date.accessioned | 2011-05-15T16:15:54Z | |
dc.date.available | 2011-05-15T16:15:54Z | |
dc.date.issued | 2003 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Letter | |
dc.identifier.citation | Cardiovascular Journal of South Africa | |
dc.identifier.citation | 14 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 10159657 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/13543 | |
dc.subject | atorvastatin | |
dc.subject | cerivastatin | |
dc.subject | fibric acid derivative | |
dc.subject | fluindostatin | |
dc.subject | hydroxymethylglutaryl coenzyme A reductase inhibitor | |
dc.subject | mevinolin | |
dc.subject | nitric oxide | |
dc.subject | phenylephrine | |
dc.subject | pravastatin | |
dc.subject | simvastatin | |
dc.subject | statine derivative | |
dc.subject | atherosclerosis | |
dc.subject | blood vessel reactivity | |
dc.subject | clinical trial | |
dc.subject | drug activity | |
dc.subject | drug effect | |
dc.subject | drug excretion | |
dc.subject | drug half life | |
dc.subject | drug mechanism | |
dc.subject | drug solubility | |
dc.subject | human | |
dc.subject | hypercholesterolemia | |
dc.subject | in vitro study | |
dc.subject | in vivo study | |
dc.subject | letter | |
dc.subject | lipid solubility | |
dc.subject | meta analysis | |
dc.subject | myalgia | |
dc.subject | rhabdomyolysis | |
dc.subject | side effect | |
dc.subject | thrombocyte aggregation | |
dc.subject | Arteries | |
dc.subject | Cholesterol | |
dc.subject | Humans | |
dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors | |
dc.subject | Muscle, Skeletal | |
dc.title | Are all statins created equal? [1] | |
dc.type | Letter |